These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 24809052)
21. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies. Avgeris M; Scorilas A Expert Opin Ther Targets; 2016 Jul; 20(7):801-18. PubMed ID: 26941073 [TBL] [Abstract][Full Text] [Related]
22. Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men. Sävblom C; Halldén C; Cronin AM; Säll T; Savage C; Vertosick EA; Klein RJ; Giwercman A; Lilja H Clin Chem; 2014 Mar; 60(3):490-9. PubMed ID: 24270797 [TBL] [Abstract][Full Text] [Related]
23. Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Lawrence MG; Lai J; Clements JA Endocr Rev; 2010 Aug; 31(4):407-46. PubMed ID: 20103546 [TBL] [Abstract][Full Text] [Related]
24. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334 [TBL] [Abstract][Full Text] [Related]
25. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Vickers AJ; Gupta A; Savage CJ; Pettersson K; Dahlin A; Bjartell A; Manjer J; Scardino PT; Ulmert D; Lilja H Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):255-61. PubMed ID: 21148123 [TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen and human glandular kallikrein: two kallikreins of the human prostate. Henttu P; Vihko P Ann Med; 1994 Jun; 26(3):157-64. PubMed ID: 7521173 [TBL] [Abstract][Full Text] [Related]
27. 4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening. McDonald ML; Parsons JK Urol Clin North Am; 2016 Feb; 43(1):39-46. PubMed ID: 26614027 [TBL] [Abstract][Full Text] [Related]
28. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Magklara A; Scorilas A; Catalona WJ; Diamandis EP Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066 [TBL] [Abstract][Full Text] [Related]
29. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Darson MF; Pacelli A; Roche P; Rittenhouse HG; Wolfert RL; Young CY; Klee GG; Tindall DJ; Bostwick DG Urology; 1997 Jun; 49(6):857-62. PubMed ID: 9187691 [TBL] [Abstract][Full Text] [Related]
30. The kallikrein-related peptidase family: Dysregulation and functions during cancer progression. Kryza T; Silva ML; Loessner D; Heuzé-Vourc'h N; Clements JA Biochimie; 2016 Mar; 122():283-99. PubMed ID: 26343558 [TBL] [Abstract][Full Text] [Related]
31. A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer. Lovell S; Zhang L; Kryza T; Neodo A; Bock N; De Vita E; Williams ED; Engelsberger E; Xu C; Bakker AT; Maneiro M; Tanaka RJ; Bevan CL; Clements JA; Tate EW J Am Chem Soc; 2021 Jun; 143(23):8911-8924. PubMed ID: 34085829 [TBL] [Abstract][Full Text] [Related]
32. [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers]. Haese A; Graefen M; Palisaar J; Huland E; Huland H Urologe A; 2003 Sep; 42(9):1172-87. PubMed ID: 14504750 [TBL] [Abstract][Full Text] [Related]
33. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. Assel M; Sjöblom L; Murtola TJ; Talala K; Kujala P; Stenman UH; Taari K; Auvinen A; Vickers A; Visakorpi T; Tammela TL; Lilja H Eur Urol Focus; 2019 Jul; 5(4):561-567. PubMed ID: 29137895 [TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Stephan C; Jung K; Diamandis EP; Rittenhouse HG; Lein M; Loening SA Urology; 2002 Jan; 59(1):2-8. PubMed ID: 11796270 [No Abstract] [Full Text] [Related]
35. Epithelial-mesenchymal transition in prostate cancer and the potential role of kallikrein serine proteases. Lawrence MG; Veveris-Lowe TL; Whitbread AK; Nicol DL; Clements JA Cells Tissues Organs; 2007; 185(1-3):111-5. PubMed ID: 17587816 [TBL] [Abstract][Full Text] [Related]
36. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. Vickers A; Cronin A; Roobol M; Savage C; Peltola M; Pettersson K; Scardino PT; Schröder F; Lilja H J Clin Oncol; 2010 May; 28(15):2493-8. PubMed ID: 20421547 [TBL] [Abstract][Full Text] [Related]
37. Development of sensitive immunoassays for free and total human glandular kallikrein 2. Väisänen V; Eriksson S; Ivaska KK; Lilja H; Nurmi M; Pettersson K Clin Chem; 2004 Sep; 50(9):1607-17. PubMed ID: 15247158 [TBL] [Abstract][Full Text] [Related]
38. MicroRNA-3162-5p-Mediated Crosstalk between Kallikrein Family Members Including Prostate-Specific Antigen in Prostate Cancer. Matin F; Jeet V; Srinivasan S; Cristino AS; Panchadsaram J; Clements JA; Batra J; Clin Chem; 2019 Jun; 65(6):771-780. PubMed ID: 31018918 [TBL] [Abstract][Full Text] [Related]
39. [PSA and hK2 in the diagnosis of prostate cancer]. Alapont Alacreu JM; Navarro Rosales S; Budía Alba A; España Furió F; Morera Martínez F; Jiménez Cruz JF Actas Urol Esp; 2008 Jun; 32(6):575-88. PubMed ID: 18655340 [TBL] [Abstract][Full Text] [Related]